Reuters logo
BRIEF-Oragenics says U.S. FDA grants fast track designation for development of co's AG013 for oral mucositis
2016年11月21日 / 晚上8点37分 / 1 年前

BRIEF-Oragenics says U.S. FDA grants fast track designation for development of co's AG013 for oral mucositis

Nov 21 (Reuters) - Oragenics Inc :

* U.S. FDA grants fast track designation for the development of Oragenics’ AG013 for oral mucositis

* Oragenics - expects to file an Investigational New Drug (IND) update and initiate a phase 2 study with AG013 in United States and Europe in early 2017 Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below